Download PDF
Der Klinikarzt 2014; 43(S 01): 6-11
DOI: 10.1055/s-0034-1377049
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Thrombolyse bei akuter Lungenembolie – Risikostratifizierung, risikoadaptierte Diagnostik und Therapie

Thrombolysis of acute pulmonary embolism – Risk stratification, risk-adjusted diagnostic and management algorithms
Mareike Lankeit
1   Centrum für Thrombose und Hämostase, Universitätsmedizin Mainz
,
Stavros Konstantinides
1   Centrum für Thrombose und Hämostase, Universitätsmedizin Mainz
› Author Affiliations
Further Information

Publication History

Publication Date:
07 May 2014 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Strategien zur Risikostratifizierung und risikoadaptierten Diagnostik und Therapie von Patienten mit akuter Lungenembolie befinden sich derzeit in einer Phase des Umbruchs. Für die neuen europäischen Leitlinien, die Mitte des Jahres 2014 erscheinen sollen, werden umfangreiche Überarbeitungen unter anderem auch hinsichtlich der Indikation zur Thrombolyse bei normotensiven Patienten mit „intermediärem“ Risiko erwartet. In diesem Artikel werden die Empfehlungen zur Thrombolyse bei Patienten mit akuter Lungenembolie zusammengefasst unter besonderer Berücksichtigung aktueller Studiendaten zur thrombolytischen Therapie bei Patienten mit „intermediärem“ Risiko.

Summary

Currently strategies for risk stratification and risk-adjusted diagnostic and management algorithms of patients with acute pulmonary embolism underlie considerable progress and transition. For the new European guidelines, publication expected for mid 2014, considerable changes are expected among others regarding the indication for thrombolysis of normotensive patients with intermediate-risk. This article summarises the recommendations for thrombolysis of patients with acute pulmonary embolism with special consideration of recent findings from clinical trials regarding thrombolysis of intermediate-risk patients.

Key words

Risk stratification - thrombolysis - PEITHO - bleeding risk
 

  • Literatur

  • 1 Kearon C, Akl EA, Comerota AJ et al. Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl) e419S-e494S
    CrossrefPubMedGoogle Scholar
  • 2 Torbicki A, Perrier A, Konstantinides SV et al. Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 29: 2276-2315
    CrossrefPubMedGoogle Scholar
  • 3 Konstantinides S, Tiede N, Geibel A et al. Comparison of alteplase versus heparin for resolution of major pulmonary embolism. Am J Cardiol 1998; 82: 966-970
    CrossrefPubMedGoogle Scholar
  • 4 Miller GA, Sutton GC, Kerr IH et al. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. Br Heart J 1971; 33: 616-616
    PubMedGoogle Scholar
  • 5 Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 2004; 110: 744-749
    CrossrefPubMedGoogle Scholar
  • 6 Stein PD, Matta F. Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused. Am J Med 2012; 125: 465-470
    CrossrefPubMedGoogle Scholar
  • 7 Konstantinides S, Goldhaber SZ. Pulmonary embolism: risk assessment and management. Eur Heart J 2012; 33: 3014-3022
    CrossrefPubMedGoogle Scholar
  • 8 Konstantinides S, Geibel A, Heusel G et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002; 347: 1143-1150
    CrossrefPubMedGoogle Scholar
  • 9 Becattini C, Agnelli G, Salvi A et al. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res 2010; 125: e82-e86
    CrossrefPubMedGoogle Scholar
  • 10 The PEITHO Steering Committee. Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial. Am Heart J 2012; 163: 33-38
    CrossrefPubMedGoogle Scholar
  • 11 Lankeit M, Konstantinides S. Thrombolysis for pulmonary embolism: Past, present and future. Thromb Haemost 2010; 103: 877-883
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Stein PD, Matta F, Steinberger DS, Keyes DC. Intracerebral hemorrhage with thrombolytic therapy for acute pulmonary embolism. Am J Med 2012; 125: 50-56
    CrossrefPubMedGoogle Scholar
  • 13 Sharifi M, Bay C, Skrocki L et al. Moderate Pulmonary Embolism Treated With Thrombolysis (from the „MOPETT“ Trial). Am J Cardiol 2013; 111: 273-277
    CrossrefPubMedGoogle Scholar
  • 14 Armstrong PW, Gershlick AH, Goldstein P et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 2013; 368: 1379-1387
    CrossrefPubMedGoogle Scholar
  • 15 Kuo WT, Gould MK, Louie JD et al. Catheter-directed therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques. J Vasc Interv Radiol 2009; 20: 1431-1440
    CrossrefPubMedGoogle Scholar
  • 16 Kucher N, Boekstegers P, Muller OJ et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 2014; 129: 479-486
    CrossrefPubMedGoogle Scholar
  • 17 Lankeit M, Konstantinidis S. Aktuelle Therapie und Sekundärprävention der Lungenembolie. Der Kardiologe 2013; 7: 217-230
    CrossrefPubMedGoogle Scholar